Opsonix, Inc.

Opsonix, Inc. is a biotechnology startup founded in 2014, specializing in the development and commercialization of a revolutionary pathogen-extracting therapy. The company's proprietary pathogen-capture proteins, particularly the advanced FcMBL, have the capability to bind a wide range of microorganisms and toxins from the bloodstream, presenting a broad-spectrum approach to tackling blood-borne infectious diseases, notably sepsis. The incorporation of FcMBL into an extracorporeal medical device marks a significant leap in the treatment of systemic infections, specifically the underlying causes of sepsis. Opsonix's innovative approach has garnered investor interest, with the latest noteworthy investment being a $1.25M Debt Financing injection on 27 October 2017. This injection reflects the confidence of investors in the potential impact of Opsonix's pathogen-extracting therapy in revolutionizing the treatment landscape for infectious diseases. As the company continues to make strides in the biotechnology and health care sectors, it stands as an intriguing prospect for venture capital consideration.